The FDA’s Vaccines and Related Biological Products Advisory Committee met Thursday to assess whether the Covid-19 vaccine needs to be updated, with the committee voting 21-0 in favor of a new monovalent, XBB lineage for shots likely coming this fall.
Pfizer/BioNTech, Moderna and Novavax all presented on what they are likely to have ready in the coming months, with all three vaccines potentially ready as soon as later this summer. Pfizer, for instance, noted that they could have an XBB.1.5 monovalent version available as soon as the end of next month, or an XBB.1.16 monovalent vaccine in August.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters